
Flovent is owned by GSK plc, the British pharmaceutical company listed on the London Stock Exchange and NYSE (GSK). GSK discontinued branded Flovent HFA and Flovent Diskus on January 1, 2024, but retains the trademark and continues to manufacture the identical medicine as authorized generics distributed by Prasco Laboratories. The first true generic competitor won FDA approval in March 2026.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Flovent | GSK plc | Wholly owned |
Fluticasone propionate emerged from Glaxo's steroid chemistry program in the 1980s as a potent topical and inhaled corticosteroid with low systemic absorption. Glaxo first introduced it in the United Kingdom as Flixotide, and the FDA approved the US version, Flovent, on March 27, 1996, for the maintenance treatment of asthma as prophylactic therapy.
The brand expanded through several device generations. Flovent Rotadisk and the original CFC-propelled inhalation aerosol gave way to Flovent Diskus, a dry powder inhaler approved in 2000, and Flovent HFA, a hydrofluoroalkane metered-dose inhaler approved in May 2004 after the phase-out of ozone-depleting CFC propellants. Glaxo Wellcome's merger created GSK in 2000, and Flovent became one of the company's core respiratory products alongside Advair, the fluticasone-salmeterol combination.
For roughly three decades, Flovent was among the most prescribed controller inhalers in the United States, particularly for children, since it carried approval for patients as young as four years old. Pediatric asthma guidelines recommended daily inhaled corticosteroid use for persistent asthma, and Flovent's established safety record made it a default choice for many pediatricians.
The economics of the brand shifted under the American Rescue Plan Act. That law eliminated the cap on Medicaid rebates for drugs with price increases above inflation, substantially raising the rebate liability for legacy branded products like Flovent. In May 2022, GSK launched an authorized generic of Flovent HFA through Prasco Laboratories, a longstanding partner that had distributed GSK's Flonase authorized generic since 2009. In October 2022, GSK announced it would discontinue branded Flovent HFA and Flovent Diskus effective January 1, 2024, allowing a transition period of roughly 15 months.
The transition did not go smoothly. Many pharmacy benefit managers declined to cover the authorized generics because they offered smaller rebates than the branded product had, leaving some plans with higher out-of-pocket costs or no covered fluticasone inhaler at all. A 2025 study found that some children stopped using inhaled corticosteroids entirely after the discontinuation, increasing their risk of asthma attacks. GSK responded in December 2024 by taking steps to support patient access to the authorized generic versions.
True generic competition arrived on March 3, 2026, when the FDA approved Glenmark Specialty SA's fluticasone propionate inhalation aerosol at 44 micrograms per actuation, the first generic therapeutically equivalent to Flovent HFA. Glenmark received 180 days of generic exclusivity and began distribution the same month. Another fluticasone HFA product is also distributed by RPK Pharmaceuticals under separate arrangements.
What does GSK own?
GSK owns a portfolio of prescription pharmaceuticals and vaccines. Its key products include Shingrix (shingles vaccine, GBP 3.6 billion in FY2025), Trelegy (respiratory, GBP 3.0 billion), the HIV franchise (GBP 7.7 billion including Dovato and Cabenuva), Arexvy (RSV vaccine), Nucala (respiratory), and Bexsero (meningitis vaccine). GSK previously owned consumer healthcare brands including Sensodyne, Advil, and Centrum, but these were spun off as Haleon plc in July 2022.
Is GSK publicly traded?
Yes, GSK plc is publicly traded on the London Stock Exchange and the New York Stock Exchange, both under the ticker symbol GSK. The company has a dispersed shareholder base dominated by institutional investors including BlackRock and Vanguard. GSK has been publicly traded since its formation in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.
Who is the CEO of GSK?
Luke Miels became CEO of GSK on January 1, 2026, succeeding Dame Emma Walmsley. Miels previously served as GSK's Chief Commercial Officer. Walmsley led GSK for nearly nine years, oversaw the Haleon demerger, and steered the company through the Zantac litigation. She remains with the company until September 30, 2026 to support the transition.
Where is GSK headquartered?
GSK is headquartered in London, United Kingdom. The company's corporate offices are in Brentford, West London. GSK has major operations in the United States (approximately 15,000 employees), Europe, and emerging markets, with manufacturing facilities in the UK, U.S., Singapore, and India.
How many brands does GSK own?
GSK owns a portfolio of approximately 20 key prescription medicines and vaccines. The most significant by revenue are Shingrix, the HIV franchise (Dovato, Cabenuva, Juluca), Trelegy, Nucala, Arexvy, Bexsero, and oncology drugs Ojemda and Blenrep. The company does not own consumer healthcare brands, as these were spun off as Haleon in 2022.
Who owns GSK?
GSK is a publicly traded company with a dispersed shareholder base. No single shareholder controls the company. Major institutional investors include BlackRock, Vanguard Group, and other large asset management firms. The company is governed by a board of directors chaired by Sir Jonathan Symonds, with CEO Luke Miels responsible for day-to-day operations.
What was the Zantac litigation?
Zantac (ranitidine) was withdrawn from the U.S. market in 2020 after the FDA found that it contained NDMA, a probable carcinogen. Approximately 80,000 lawsuits were filed alleging Zantac caused cancer. GSK agreed in October 2024 to pay up to $2.3 billion to settle the U.S. claims without admitting liability. By the end of 2025, GSK had paid GBP 1.9 billion, with the remaining GBP 0.6 billion expected in 2026. The company described the settlement process as materially complete.
The most significant controversy surrounding Flovent concerns the circumstances of its discontinuation rather than any product defect. When GSK withdrew the branded inhalers in January 2024, many pharmacy benefit managers excluded the authorized generics from formularies because they carried smaller rebates. Some patients faced higher costs or lost coverage, and a 2025 study linked the transition to children discontinuing inhaled corticosteroids and experiencing increased asthma attack risk. GSK stated that coverage decisions were made independently by Prasco and payers and that it moved in December 2024 to improve access.
The brand also illustrates the broader policy debate over the American Rescue Plan Act's Medicaid rebate changes, which GSK cited as the reason the branded product became uneconomical. Critics argued the episode showed how rebate structures, not clinical need, determined whether a widely used medicine remained on formularies.
On product safety, fluticasone propionate has an established record spanning three decades. Its label carries class-standard warnings including oral candidiasis, immunosuppression, and reduced growth velocity in children. No major manufacturing recall of Flovent has been recorded in FDA enforcement actions, and the March 2026 Glenmark generic approval proceeded with the same warnings and precautions as the reference product.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Strides Pharma Science | India | 1996 | Mass market | United states | All Genders |
Market Positioning: Flovent competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by GSK plc, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Flovent which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Flovent which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Global Medical Response
America's largest air ambulance membership network, covering more than 3 million members across 38 states, operated by Global Medical Response.
AirMedCare Network is privately owned, unlike Flovent which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Flovent which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by All Family Pharmacy LLC
Boca Raton mail-order pharmacy at allfamilypharmacy.com known for direct-to-consumer access to ivermectin, hydroxychloroquine, and 200-plus medications.
All Family Pharmacy is privately owned, unlike Flovent which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Opella
Over-the-counter allergy relief brand containing fexofenadine, originally developed by Hoechst Marion Roussel and approved by the FDA in 1996. Owned since April 2025 by Opella, the consumer healthcare company carved out of Sanofi and controlled by Clayton, Dubilier and Rice.
Allegra is privately owned, unlike Flovent which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.